Close Menu

NEW YORK (GenomeWeb) – Qiagen announced today that it has partnered with Mirati Therapeutics to co-develop and commercialize a companion diagnostic for Mirati's glesatinib, a targeted therapy under development for the treatment of non-small cell lung cancer.

The diagnostic is intended to guide physicians in whether or not to prescribe glesatinib to NSCLC patients by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

 Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.